Another study by Seto et al., investigated the therapeutic effects of combining bevacizumab with atezolizumab at a fixed dosage for advanced NSCLC patients with PD-L1 expression exceeding 50% but without EGFR/ALK/ROS1 alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.